Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used for the treatment of breast cancer and gastric cancer. Herceptin is mainly used to treat patients suffering from cancer and diagnosed with HER2 receptor positive. Herceptin mechanism of action is binding itself to HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals and thus decreasing the mutation of cells. Herceptin acts as an immune targeted therapy for breast cancer patients.
Market Dynamics
Product approvals and launches are the factors driving the growth of the global herceptin biosimilar market. For instance, in February 2020, Pfizer Inc., a biotechnology and pharmaceutical company in the U.S., launched the trastuzumab biosimilar, Trazimera, for treatment of human epidermal growth receptor causing breast cancer and metastatic gastric cancer.
Key features of the study
• This report provides in-depth analysis of the global herceptin biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Herceptin biosimilar market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd
• Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
• The global herceptin biosimilar market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herceptin biosimilar market.
Market Segmentation
• By Indication
o Breast Cancer
o Gastric Cancer
o Others
• By Distribution Channel
o Hospitals
o Oncology Centers
o Others
• Global Herceptin Biosimilar Market, By Region
o North America
 U.S.
 Canada
o Latin America
 Brazil
 Mexico
 Argentina
 Rest of Latin America
o Europe
 Germany
 U.K.
 France
 Italy
 Spain
 Russia
 Rest of Europe
o Asia Pacific
 China
 India
 Japan
 Australia
 South Korea
 ASEAN
 Rest of Asia Pacific
o Middle East
 GCC
 Israel
 Rest of Middle East
o Africa
 South Africa
 Central Africa
 North Africa
• Key Players
o Amgen Inc.
o AryoGen Biopharma
o Biocon Limited
o Celltrion Inc.
o Pfizer Inc.
o Merck & Co., Inc.
o Accord Healthcare Ltd
o Gedeon Richter Plc
o Genor Biopharma Company Ltd
o Mabion SA
o Mylan N.V
o Roche Holding AG
o Samsungbioepis Co., Ltd.

Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
 Market Definition and Scope
o Executive Summary
 Market Snapshot, By Indication
 Market Snapshot, By Distribution Channel
 Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
 Drivers
 Restraints
 Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Herceptin Biosimilar Market, By Indication, 2021 – 2033, (USD Billion)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022– 2033
 Segment Trends
o Breast Cancer
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Gastric Cancer
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Others
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
5. Global Herceptin Biosimilar Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 – 2033
 Segment Trends
o Hospital
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Oncology Centers
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Others
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
6. Global Herceptin Biosimilar Market, By Region, 2021 – 2033, (USD Billion)
o Introduction
 Market Share Analysis, By Region, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, For Regions, 2022–2033
 Regional Trends
o North America
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.S.
o Canada
o Latin America
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o GCC
o Israel
o Rest of Middle East
o Africa
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
 Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
 Amgen Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 AryoGen Biopharma
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Biocon Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Celltrion Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Pfizer Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Merck & Co., Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Accord Healthcare Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Gedeon Richter Plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Genor Biopharma Company Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Mabion SA
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Mylan N.V
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Roche Holding AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Samsungbioepis Co,.Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us